Determination of Surface Visible Residue Limits on Pharmaceutical Plant Equipment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determination of Surface Visible Residue Limits on Pharmaceutical Plant Equipment
The minimum amount of residue that can be visually detected on a surface, i.e., visible residue limit (VRL), is demonstrated for a small number of active pharmaceutical ingredients (APIs) on a range of different surface materials typically found in API and drug product manufacturing plants.


Pharmaceutical Technology
Volume 37, Issue 2

Visible inspection is an essential component of a cleaning validation program and a requirement for compliance with good manufacturing practice (GMP). The use of inspection as the sole means of determining equipment cleanliness for pharmaceutical facilities was initially proposed by Mendenhall and Leblanc (1, 2). FDA's 1993 Guide to Inspection of Validation of Cleaning Processes, however, indicated that its use should be limited to batches of the same product, which has led to its limited exploitation to date within the industry (3). Nevertheless, this topic continues to be a subject of discussion; for example, a risk-based approach supported by visible residue limit (VRL) data has been proposed for R&D pilot plants, in conjunction with validated cleaning procedures (4–9).

Potential benefits of the use of visual inspection alone include significant time savings compared with the commonly used techniques of swab or rinse analysis, as well as the fact that visual inspection, in principle, has the capability of testing 100% of the equipment surface. The risks associated with factors that have been demonstrated to affect VRL measurements, however, need to be managed. These factors include observer subjectivity, lighting level, distance, viewing angle, and inspection methodology (4, 6, 8, 9).

Data published previously on VRLs have largely focused on evaluating limits on stainless-steel metal plates. For this study, using a small number of active pharmaceutical ingredients (APIs), a range of plates was assessed of different surface types typically found in API and drug-product manufacturing plants. In addition, the potential for variance in the VRL with metal-surface roughness was investigated.

Method

Surfaces examined comprised borosilicate clear glass (QVF), white polytetrafluoroethylene (PTFE), Pfaudler World Wide Glass white (9125) and dark blue (9115) Glasteel, and stainless steel S316. Metal plates of different surface roughness were examined, with the range selected to encompass actual measured values for items of equipment in the manufacturing facilities, typically between 0.0 to 0.7 µm. Additionally, a 1.1-µm surface roughness was examined to determine the consequence of any deterioration in condition of the metal. The surface roughness was measured using a Surtronic Duo instrument (Taylor Hobson), and the variation in roughness across the plates was within 10% of the stated mean.

The method was designed to minimize variables of subjectivity, environment, and solvent effects, in accordance with the conclusions reported in previous studies. The VRL evaluations were conducted under the controlled conditions of an analytical-science laboratory, determined as representative of a typical manufacturing room, with ambient lighting of approximately 300 lux. Solutions of APIs to be tested were prepared by dissolution in methanol, which was selected because the solvent leaves no surface residue and dries to a more even coverage, with minimal sample rings. APIs known to be stable to aerial oxidation were selected.

The solutions were applied dropwise to 10 x 10 cm flat plates of the various materials of construction, with concentrations set to ensure complete, even coverage of plates. A starting coverage of 10 µg/dm2 was used because it met the minimum requirements to enable useful application in actual plant equipment. Each plate was left to dry naturally before visual examination. If the API was not visible, the loading operation was repeated to increase the amount of material on the surface in a stepwise fashion until it could be visually detected on the plate. Four observers, trained as cleaning inspectors, viewed each plate independently, from a distance of between 6 and 50 inches before comparing findings. The observations were all conducted in the same location in the laboratory to minimize any variability due to lighting conditions as well as to ensure that every possible viewing angle was assessed. Each examination was conducted first in ambient laboratory lighting, followed with additional aid of a portable spotlight source. The angle and distance of the spotlight and observer were varied each time to maximize the capability to view any contamination, taking into consideration surface reflectivity. The clear glass plates were viewed from both upper and lower sides (i.e., looking directly onto and through the glass) by means of one, independent person manipulating the plate with a second person performing the role of inspector.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here